Title 21 — Food and Drugs
Part D · Chapter 13 — Drug Abuse Prevention and Control
§ 842. Prohibited acts B
Statutory text
Unlawful acts
It shall be unlawful for any person—
who is subject to the requirements of part C to distribute or dispense a controlled substance in violation of section 829 of this title;
who is a registrant to distribute or dispense a controlled substance not authorized by his registration to another registrant or other authorized person or to manufacture a controlled substance not authorized by his registration;
who is a registrant to distribute a controlled substance in violation of section 825 of this title;
to remove, alter, or obliterate a symbol or label required by section 825 of this title;
to refuse or negligently fail to make, keep, or furnish any record, report, notification, declaration, order or order form, statement, invoice, or information required under this subchapter or subchapter II;
to refuse any entry into any premises or inspection authorized by this subchapter or subchapter II;
to remove, break, injure, or deface a seal placed upon controlled substances pursuant to section 824(f) or 881 of this title or to remove or dispose of substances so placed under seal;
to use, to his own advantage, or to reveal, other than to duly authorized officers or employees of the United States, or to the courts when relevant in any judicial proceeding under this subchapter or subchapter II, any information acquired in the course of an inspection authorized by this subchapter concerning any method or process which as a trade secret is entitled to protection, or to use to his own advantage or reveal (other than as authorized by section 830 of this title) any information that is confidential under such section;
who is a regulated person to engage in a regulated transaction without obtaining the identification required by 830(a)(3) of this title.1
negligently to fail to keep a record or make a report under section 830 of this title or negligently to fail to self-certify as required under section 830 of this title;
to distribute a laboratory supply to a person who uses, or attempts to use, that laboratory supply to manufacture a controlled substance or a listed chemical, in violation of this subchapter or subchapter II, with reckless disregard for the illegal uses to which such a laboratory supply will be put;
who is a regulated seller, or a distributor required to submit reports under subsection (b)(3) of section 830 of this title—
to sell at retail a scheduled listed chemical product in violation of paragraph (1) of subsection (d) of such section, knowing at the time of the transaction involved (independent of consulting the logbook under subsection (e)(1)(A)(iii) of such section) that the transaction is a violation; or
to knowingly or recklessly sell at retail such a product in violation of paragraph (2) of such subsection (d);
who is a regulated seller to knowingly or recklessly sell at retail a scheduled listed chemical product in violation of subsection (e) of such section;
who is a regulated seller or an employee or agent of such seller to disclose, in violation of regulations under subparagraph (C) of section 830(e)(1) of this title, information in logbooks under subparagraph (A)(iii) of such section, or to refuse to provide such a logbook to Federal, State, or local law enforcement authorities;
to distribute a scheduled listed chemical product to a regulated seller, or to a regulated person referred to in section 830(b)(3)(B) of this title, unless such regulated seller or regulated person is, at the time of such distribution, currently registered with the Drug Enforcement Administration, or on the list of persons referred to under section 830(e)(1)(B)(v) of this title;
to violate subsection (e) of section 825 of this title; 2 or
in the case of a registered manufacturer or distributor of opioids, to fail to review the most recent information, directly related to the customers of the manufacturer or distributor, made available by the Attorney General in accordance with section 827(f) of this title.
As used in paragraph (11), the term “laboratory supply” means a listed chemical or any chemical, substance, or item on a special surveillance list published by the Attorney General, which contains chemicals, products, materials, or equipment used in the manufacture of controlled substances and listed chemicals. For purposes of paragraph (11), there is a rebuttable presumption of reckless disregard at trial if the Attorney General notifies a firm in writing that a laboratory supply sold by the firm, or any other person or firm, has been used by a customer of the notified firm, or distributed further by that customer, for the unlawful production of controlled substances or listed chemicals a firm distributes and 2 weeks or more after the notification the notified firm distributes a laboratory supply to the customer. For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title.
Manufacture
It shall be unlawful for any person who is a registrant to manufacture a controlled substance in schedule I or II, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical, which is—
not expressly authorized by his registration and by a quota assigned to him pursuant to section 826 of this title; or
in excess of a quota assigned to him pursuant to section 826 of this title.
Penalties
Except as provided in subparagraph (B), (C), or (D) of this paragraph and paragraph (2), any person who violates this section shall, with respect to any such violation, be subject to a civil penalty of not more than $25,000. The district courts of the United States (or, where there is no such court in the case of any territory or possession of the United States, then the court in such territory or possession having the jurisdiction of a district court of the United States in cases arising under the Constitution and laws of the United States) shall have jurisdiction in accordance with section 1355 of title 28 to enforce this paragraph.
Except as provided in clause (ii), in the case of a violation of paragraph (5), (10), or (17) of subsection (a), the civil penalty shall not exceed $10,000.
In the case of a violation described in clause (i) committed by a registered manufacturer or distributor of opioids and related to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 827(f) of this title, the penalty shall not exceed $100,000.
In the case of a violation of paragraph (16) of subsection (a) of this section by an importer, exporter, manufacturer, or distributor (other than as provided in subparagraph (D)), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of paragraph (16) of subsection (a).
In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of paragraph (16) of subsection (a) of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term “at the retail level” refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of such paragraph (16) of subsection (a) shall be considered a separate violation.
If a violation of this section is prosecuted by an information or indictment which alleges that the violation was committed knowingly and the trier of fact specifically finds that the violation was so committed, such person shall, except as otherwise provided in subparagraph (B) or (D) of this paragraph, be sentenced to imprisonment of not more than one year or a fine under title 18, or both.
If a violation referred to in subparagraph (A) was committed after one or more prior convictions of the offender for an offense punishable under this paragraph (2), or for a crime under any other provision of this subchapter or subchapter II or other law of the United States relating to narcotic drugs, marihuana, or depressant or stimulant substances, have become final, such person shall be sentenced to a term of imprisonment of not more than 2 years, a fine under title 18, or both.
In addition to the penalties set forth elsewhere in this subchapter or subchapter II, any business that violates paragraph (11) of subsection (a) shall, with respect to the first such violation, be subject to a civil penalty of not more than $250,000, but shall not be subject to criminal penalties under this section, and shall, for any succeeding violation, be subject to a civil fine of not more than $250,000 or double the last previously imposed penalty, whichever is greater.
In the case of a violation described in subparagraph (A) that was a violation of paragraph (5), (10), or (17) of subsection (a) committed by a registered manufacturer or distributor of opioids that relates to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 827(f) of this title, the criminal fine under title 18 shall not exceed $500,000.
Except under the conditions specified in paragraph (2) of this subsection, a violation of this section does not constitute a crime, and a judgment for the United States and imposition of a civil penalty pursuant to paragraph (1) shall not give rise to any disability or legal disadvantage based on conviction for a criminal offense.
If a regulated seller, or a distributor required to submit reports under section 830(b)(3) of this title, violates paragraph (12) of subsection (a) of this section, or if a regulated seller violates paragraph (13) of such subsection, the Attorney General may by order prohibit such seller or distributor (as the case may be) from selling any scheduled listed chemical product. Any sale of such a product in violation of such an order is subject to the same penalties as apply under paragraph (2).
An order under subparagraph (A) may be imposed only through the same procedures as apply under section 824(c) of this title for an order to show cause.
Footnotes
- 1 So in original. Probably should be “section 830(a)(3) of this title;”.
- 2 See References in Text note below.
Legislative history
Reconstructed from this section’s Code source credit and amendment notes, resolved against the local Statutes at Large. Editorial notes are evidence, not the law that made the change.
Controlled Substances Act
Pub. L. 91–513 title II § 402 · 84 Stat. 1236
Enacted · 21 U.S.C. § 842
Pub. L. 91–513, title II, § 402, Oct. 27, 1970, 84 Stat. 1262
Source evidence
Code source credit
Pub. L. 91–513, title II, § 402, Oct. 27, 1970, 84 Stat. 1262Enacted provision · exact public law section
Sec. 402. prohibited acts—penalties (a) It shall be unlawful for any person— (1) who is subject to the requirements of part C to distribute or dispense a controlled substance in violation of section 309; (2) who is a registrant to distribute or dispense a controlled substance not authorized by his registration to another registrant, or other authorized person or to manufacture a controlled substance not authorized by his registration; (3) who is a registrant to distribute a controlled substance in violation of section 305 of this title; (4) to remove, alter, or obliterate a symbol or label required by section 305 of this title: (5) to refuse or fail to make, keep, or furnish any record, report, notification, declaration, order or order form, statement, Post, p. 1285 invoice, or information required under this title or title III; (6) to refuse any entry into any premises or inspection authorized by this title or title III; (7) to remove, break, injure, or deface a seal placed upon controlled Ante, p. 1256 Post, p. 1276 substances pursuant to section 304(f) or 511 or to remove or dispose of substances so placed under seal; or (8) to use, to his own advantage, or to reveal, other than to duly authorized officers or employees of the United States, or to the courts when relevant in any judicial proceeding under this title or title III, any information acquired in the course of an inspection authorized by this title concerning any method or process which as a trade secret is entitled to protection. (b) It shall be unlawful for any person who is a registrant to manufacture a controlled substance in schedule I or II which is— (1) not expressly authorized by his registration and by a quota assigned to him pursuant to section 306; or (2) in excess of a quota assigned to him pursuant to section 306. (c) (1) Except as provided in paragraph (2), any person who violates this section shall, with respect to any such violation, be subject Jurisdiction. to a civil penalty of not more than $25,000. The district courts of the United States (or, where there is no such court in the ease of any territory or possession of the United States, then the court in such territory or possession having the jurisdiction of a district court of the United States in cases arising under the Constitution and laws of the United States) shall have jurisdiction in accordance with section 1355 62 Stat. 934. of title 28 of the United States Code to enforce this paragraph. (2) (A) If a violation of this section is prosecuted by an information or indictment which alleges that the violation was committed knowingly and the trier of fact specifically finds that the violation was so committed, such person shall, except as otherwise provided in subparagraph (B) of this paragraph, be sentenced to imprisonment of Penalty. not more than one year or a fine of not more than $25,000, or both. (B) If a violation referred to in subparagraph (A) was committed after one or more prior convictions of the offender for an offense punishable under this paragraph (2), or for a crime under any other provision of this title or title III or other law of the United States Post, p. 1285. relating to narcotic drugs, marihuana, or depressant or stimulant substances, have become final, such person shall be sentenced to a term Penalty. of imprisonment of not more than 2 years, a fine of $50,000, or both. (3) Except under the conditions specified in paragraph (2) of Exception. this subsection, a violation of this section does not constitute a crime, and a judgment for the United States and imposition of a civil penalty Pursuant to paragraph (1) shall not give rise to any disability or legal disadvantage based on conviction for a criminal offense.Psychotropic Substances Act of 1978
Pub. L. 95–633 § 202(b)(1) · 92 Stat. 3768
Added · 21 U.S.C. § 842(a)(9)
Pub. L. 95–633, § 202(b)(1), added par. (9)
Source evidence
Code amendment note
Subsec. (a)(9). Pub. L. 95–633, § 202(b)(1), added par. (9).Enacted provision · exact public law section
(1) Section 402 (a) of such Act (21 U.S.C. 842(a)) is amended— (A) by striking out “or” at the end of paragraph (7); (B) by striking out the period at the end of paragraph (8) and inserting in lieu thereof “; or”; and (C) by adding after paragraph (8) the following new paragraph: “(9) to distribute or sell piperidine in violation of regulations Ante, p. 3775. established under section 310(a)(2), respecting presentation of identification.”.Psychotropic Substances Act of 1978
Pub. L. 95–633 § 202(b)(2) · 92 Stat. 3768
Added · 21 U.S.C. § 842(c)(2)(C)
Pub. L. 95–633, § 202(b)(2), added subpar. (C)
Source evidence
Code amendment note
Subsec. (c)(2)(C). Pub. L. 95–633, § 202(b)(2), added subpar. (C).Enacted provision · exact public law section
(2) Section 402(c)(2) of such Act (21 U.S.C. 842(c)(2)) is amended by adding after subparagraph (B) the following new subparagraph: “(C) Subparagraphs (A) and (B) shall not apply to a violation of subsection (a)(5) with respect to a refusal or failure to make a report required under section 310(a) (relating to piperidine reporting)”.Chemical Diversion and Trafficking Act of 1988
Pub. L. 100–690 § 6056(a) · 102 Stat. 4181
Inserted · 21 U.S.C. § 842(a)(8)
Pub. L. 100–690, § 6056(a), inserted “, or to use to his own advantage or reveal (other than as authorized by section 830 of this title) any information that is confidential under such section” after “protection”
Source evidence
Code amendment note
Subsec. (a)(8). Pub. L. 100–690, § 6056(a), inserted “, or to use to his own advantage or reveal (other than as authorized by section 830 of this title) any information that is confidential under such section” after “protection”.Enacted provision · exact public law section
(a) Confidential Information Amendment.— Section 402(a)(8) of the Controlled Substances Act (21 U.S.C. 842(a)(8)) is amended by inserting after “protection” the following: “, or to use to his own advantage or reveal (other than as authorized by section 310) any information that is confidential under such section”.Chemical Diversion and Trafficking Act of 1988
Pub. L. 100–690 § 6056(b) · 102 Stat. 4181
Amended · 21 U.S.C. § 842(a)(9)
Pub. L. 100–690, § 6056(b), amended par. (9) generally. Prior to amendment, par. (9) read as follows: “to distribute or sell piperidine in violation of regulations established under section 830(a)(2) of this title, respecting presentation of identification.”
Source evidence
Code amendment note
Subsec. (a)(9). Pub. L. 100–690, § 6056(b), amended par. (9) generally. Prior to amendment, par. (9) read as follows: “to distribute or sell piperidine in violation of regulations established under section 830(a)(2) of this title, respecting presentation of identification.”Enacted provision · exact public law section
(b) Identification Amendment.— Section 402(a)(9) of the Controlled Substances Act (21 U.S.C. 842(a)(9)) is amended to read as follows: “(9) who is a regulated person to engage in a regulated transaction without obtaining the identification required by 310(a)(3).”.Chemical Diversion and Trafficking Act of 1988
Pub. L. 100–690 § 6056(d) · 102 Stat. 4181
Added · 21 U.S.C. § 842(a)(10)
Pub. L. 100–690, § 6056(d), added par. (10)
Source evidence
Code amendment note
Subsec. (a)(10). Pub. L. 100–690, § 6056(d), added par. (10).Enacted provision · exact public law section
(d) Records Violations.— Section 402(a) of the Controlled Substances Act (21 U.S.C. 842(a)) is amended— (1) in paragraph (8), as amended by subsection (a) of this section, by striking out “or” at the end of the paragraph; (2) in paragraph (9), as amended by subsection (b) of this section, by striking out the period at the end of the paragraph and inserting in lieu thereof “; or”; and (3) by adding at the end the following new paragraph: “(10) to fail to keep a record or make a report under section 310.”.Chemical Diversion and Trafficking Act of 1988
Pub. L. 100–690 § 6056(c) · 102 Stat. 4181
Struck · 21 U.S.C. § 842(c)(2)(C)
Pub. L. 100–690, § 6056(c), struck out subpar. (C) which read as follows: “Subparagraphs (A) and (B) shall not apply to a violation of subsection (a)(5) of this section with respect to a refusal or failure to make a report required under section 830(a) of this title (relating to piperidine reporting).”
Source evidence
Code amendment note
Subsec. (c)(2)(C). Pub. L. 100–690, § 6056(c), struck out subpar. (C) which read as follows: “Subparagraphs (A) and (B) shall not apply to a violation of subsection (a)(5) of this section with respect to a refusal or failure to make a report required under section 830(a) of this title (relating to piperidine reporting).”Enacted provision · exact public law section
(c) Technical Amendment.— Section 402(c)(2) of the Controlled Substances Act (21 U.S.C. 842(c)(2)) is amended by striking out subparagraph (C).Comprehensive Methamphetamine Control Act of 1996
Pub. L. 104–237 § 205(a) · 110 Stat. 3099
Added · 21 U.S.C. § 842(a)
Pub. L. 104–237, § 205(a), added par. (11) and closing provisions
Source evidence
Code amendment note
Subsec. (a). Pub. L. 104–237, § 205(a), added par. (11) and closing provisions.Enacted provision · exact public law section
(a) Offenses.— Section 402(a) of the Controlled Substances Act (21 U.S.C. 842(a)) is amended— (1) in paragraph (9), by striking “or” after the semicolon; (2) in paragraph (10), by striking the period and inserting “; or”; and (3) by adding at the end the following: “(11) to distribute a laboratory supply to a person who uses, or attempts to use, that laboratory supply to manufacture a controlled substance or a listed chemical, in violation of this title or title III, with reckless disregard for the illegal uses to which such a laboratory supply will be put. As used in paragraph (11), the term ‘laboratory supply’ means a listed chemical or any chemical, substance, or item on a special surveillance list published by the Attorney General, which contains chemicals, products, materials, or equipment used in the manufacture of controlled substances and listed chemicals. For purposes of paragraph (11), there is a rebuttable presumption of reckless disregard at trial if the Attorney General notifies a firm in writing that a laboratory supply sold by the firm, or any other person or firm, has been used by a customer of the notified firm, or distributed further by that customer, for the unlawful production of controlled substances or listed chemicals a firm distributes and 2 weeks or more after the notification the notified firm distributes a laboratory supply to the customer.”.Comprehensive Methamphetamine Control Act of 1996
Pub. L. 104–237 § 205(b) · 110 Stat. 3099
Added · 21 U.S.C. § 842(c)(2)(C)
Pub. L. 104–237, § 205(b), added subpar. (C)
Source evidence
Code amendment note
Subsec. (c)(2)(C). Pub. L. 104–237, § 205(b), added subpar. (C).Enacted provision · exact public law section
(b) Civil Penalty.— Section 402(c)(2) of the Controlled Substances Act (21 U.S.C. 842(c)(2)) is amended by adding at the end the following: “(C) In addition to the penalties set forth elsewhere in this title or title III, any business that violates paragraph (11) of subsection (a) shall, with respect to the first such violation, be subject to a civil penalty of not more than $250,000, but shall not be subject to criminal penalties under this section, and shall, for any succeeding violation, be subject to a civil fine of not more than $250,000 or double the last previously imposed penalty, whichever is greater.”.Pub. L. 105–277 § 101(b)(tI)(s117)(1) · 112 Stat. 2681
Inserted · 21 U.S.C. § 842(a)(5)
Pub. L. 105–277, § 101(b) [title I, § 117(1)], inserted “negligently” before “fail”
Source evidence
Code amendment note
Subsec. (a)(5). Pub. L. 105–277, § 101(b) [title I, § 117(1)], inserted “negligently” before “fail”.Enacted provision · exact public law section
Sec. 101. For programs, projects or activities in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999, provided as follows, to be effective as if it had been enacted into law as the regular appropriations Act: AN ACT Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 1999, and for other purposes. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999.Pub. L. 105–277 § 101(b)(tI)(s117)(2) · 112 Stat. 2681
Inserted · 21 U.S.C. § 842(a)(10)
Pub. L. 105–277, § 101(b) [title I, § 117(2)], inserted “negligently” before “to fail”
Source evidence
Code amendment note
Subsec. (a)(10). Pub. L. 105–277, § 101(b) [title I, § 117(2)], inserted “negligently” before “to fail”.Enacted provision · exact public law section
Sec. 101. For programs, projects or activities in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999, provided as follows, to be effective as if it had been enacted into law as the regular appropriations Act: AN ACT Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 1999, and for other purposes. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999.Pub. L. 105–277 § 101(b)(tI)(s117)(3) · 112 Stat. 2681
Amended · 21 U.S.C. § 842(c)(1)
Pub. L. 105–277, § 101(b) [title I, § 117(3)], designated existing provisions as subpar. (A)
Inserted · 21 U.S.C. § 842(c)(1)
Pub. L. 105–277, § 101(b) [title I, § 117(3)], inserted “subparagraph (B) of this paragraph and” before “paragraph (2)”
Added · 21 U.S.C. § 842(c)(1)
Pub. L. 105–277, § 101(b) [title I, § 117(3)], added subpar. (B)
Source evidence
Code amendment note
Subsec. (c)(1). Pub. L. 105–277, § 101(b) [title I, § 117(3)], designated existing provisions as subpar. (A), inserted “subparagraph (B) of this paragraph and” before “paragraph (2)”, and added subpar. (B).Enacted provision · exact public law section
Sec. 101. For programs, projects or activities in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999, provided as follows, to be effective as if it had been enacted into law as the regular appropriations Act: AN ACT Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 1999, and for other purposes. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999.Criminal Law Technical Amendments Act of 2002
Pub. L. 107–273 § 4002(d)(2)(B)(i) · 116 Stat. 1758
Substituted · 21 U.S.C. § 842(c)(2)(A)
Pub. L. 107–273, § 4002(d)(2)(B)(i), substituted “under title 18” for “of not more than $25,000”
Source evidence
Code amendment note
Subsec. (c)(2)(A). Pub. L. 107–273, § 4002(d)(2)(B)(i), substituted “under title 18” for “of not more than $25,000”.Enacted provision · exact public law section
(i) in subparagraph (A), by striking “of not more than $25,000” and inserting “under title 18, United States Code”; andCriminal Law Technical Amendments Act of 2002
Pub. L. 107–273 § 4002(d)(2)(B)(ii) · 116 Stat. 1758
Substituted · 21 U.S.C. § 842(c)(2)(B)
Pub. L. 107–273, § 4002(d)(2)(B)(ii), substituted “under title 18” for “of $50,000”
Source evidence
Code amendment note
Subsec. (c)(2)(B). Pub. L. 107–273, § 4002(d)(2)(B)(ii), substituted “under title 18” for “of $50,000”.Enacted provision · exact public law section
(ii) in subparagraph (B), by striking “of $50,000” and inserting “under title 18, United States Code”.Criminal Law Technical Amendments Act of 2002
Pub. L. 107–273 § 4002(b)(16) · 116 Stat. 1758
Changed · 21 U.S.C. § 842(c)(2)(C)
Pub. L. 107–273, § 4002(b)(16), realigned margins
Source evidence
Code amendment note
Subsec. (c)(2)(C). Pub. L. 107–273, § 4002(b)(16), realigned margins.Enacted provision · exact public law section
(16) Correction of indentation in controlled substances act.— Section 402(c)(2) of the Controlled Substances Act (21 U.S.C. 842(c)(2)) is amended by moving the margin of subparagraph (C) 2 ems to the left.Combat Methamphetamine Epidemic Act of 2005
Pub. L. 109–177 § 711(f)(1)(A) · 120 Stat. 192
Added · 21 U.S.C. § 842(a)(12)(14)
Pub. L. 109–177, § 711(f)(1)(A), added pars. (12) to (14)
Source evidence
Code amendment note
Subsec. (a)(12) to (14). Pub. L. 109–177, § 711(f)(1)(A), added pars. (12) to (14).Enacted provision · exact public law section
(A) In general.— Section 402(a) of the Controlled Substances Act (21 U.S.C. 842(a)) is amended— (i) in paragraph (10), by striking “or” after the semicolon; (ii) in paragraph (11), by striking the period at the end and inserting a semicolon; and (iii) by inserting after paragraph (11) the following paragraphs: “(12) who is a regulated seller, or a distributor required to submit reports under subsection (b)(3) of section 310— “(A) to sell at retail a scheduled listed chemical product in violation of paragraph (1) of subsection (d) of such section, knowing at the time of the transaction involved (independent of consulting the logbook under subsection (e)(1)(A)(iii) of such section) that the transaction is a violation; or “(B) to knowingly or recklessly sell at retail such a product in violation of paragraph (2) of such subsection (d); “(13) who is a regulated seller to knowingly or recklessly sell at retail a scheduled listed chemical product in violation of subsection (e) of such section; or “(14) who is a regulated seller or an employee or agent of such seller to disclose, in violation of regulations under subparagraph (C) of section 310(e)(1), information in logbooks under subparagraph (A)(iii) of such section, or to refuse to provide such a logbook to Federal, State, or local law enforcement authorities.” .Combat Methamphetamine Epidemic Act of 2005
Pub. L. 109–177 § 714 · 120 Stat. 192
Inserted · 21 U.S.C. § 842(b)
Pub. L. 109–177, § 714, inserted “, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical,” after “manufacture a controlled substance in schedule I or II” in introductory provisions
Source evidence
Code amendment note
Subsec. (b). Pub. L. 109–177, § 714, inserted “, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical,” after “manufacture a controlled substance in schedule I or II” in introductory provisions.Enacted provision · exact public law section
SEC. 714. PENALTIES; AUTHORITY FOR MANUFACTURING; QUOTA. Section 402(b) of the Controlled Substances Act (21 U.S.C. 842(b)) is amended by inserting after “manufacture a controlled substance in schedule I or II” the following: “, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical,”.Combat Methamphetamine Epidemic Act of 2005
Pub. L. 109–177 § 711(f)(2) · 120 Stat. 192
Added · 21 U.S.C. § 842(c)(4)
Pub. L. 109–177, § 711(f)(2), added par. (4)
Source evidence
Code amendment note
Subsec. (c)(4). Pub. L. 109–177, § 711(f)(2), added par. (4).Enacted provision · exact public law section
(2) Authority to prohibit sales by violators.— Section 402(c) of the Controlled Substances Act (21 U.S.C. 842(c)) is amended by adding at the end the following paragraph: “(4) (A) If a regulated seller, or a distributor required to submit reports under section 310(b)(3), violates paragraph (12) of subsection (a) of this section, or if a regulated seller violates paragraph (13) of such subsection, the Attorney General may by order prohibit such seller or distributor (as the case may be) from selling any scheduled listed chemical product. Any sale of such a product in violation of such an order is subject to the same penalties as apply under paragraph (2). “(B) An order under subparagraph (A) may be imposed only through the same procedures as apply under section 304(c) for an order to show cause.” .Combat Methamphetamine Enhancement Act of 2010
Pub. L. 111–268 § 4(4) · 124 Stat. 2847
Inserted · 21 U.S.C. § 842(a)
Pub. L. 111–268, § 4(4), inserted “For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title.” at end of concluding provisions
Source evidence
Code amendment note
Subsec. (a). Pub. L. 111–268, § 4(4), inserted “For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title.” at end of concluding provisions.Enacted provision · exact public law section
(4) Deadline. by inserting at the end the following: “For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 310(e)(1)(B)(v), the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 310(e)(1)(B)(v).”.Effective date note
Amendment by Pub. L. 111–268 effective 180 days after Oct. 12, 2010, see section 6(a) of Pub. L. 111–268, set out as a note under section 830 of this title.Combat Methamphetamine Enhancement Act of 2010
Pub. L. 111–268 § 5 · 124 Stat. 2847
Inserted · 21 U.S.C. § 842(a)(10)
Pub. L. 111–268, § 5, inserted “or negligently to fail to self-certify as required under section 830 of this title” before semicolon
Source evidence
Code amendment note
Subsec. (a)(10). Pub. L. 111–268, § 5, inserted “or negligently to fail to self-certify as required under section 830 of this title” before semicolon.Enacted provision · exact public law section
SEC. 5. NEGLIGENT FAILURE TO SELF-CERTIFY AS REQUIRED. Section 402(a)(10) of the Controlled Substances Act (21 U.S.C. 842(a)(10)) is amended by inserting before the semicolon the following: “or negligently to fail to self-certify as required under section 310”.Effective date note
Amendment by Pub. L. 111–268 effective 180 days after Oct. 12, 2010, see section 6(a) of Pub. L. 111–268, set out as a note under section 830 of this title.Combat Methamphetamine Enhancement Act of 2010
Pub. L. 111–268 § 4(1) · 124 Stat. 2847
Added · 21 U.S.C. § 842(a)(15)
Pub. L. 111–268, § 4(1)–(3), added par. (15)
Source evidence
Code amendment note
Subsec. (a)(15). Pub. L. 111–268, § 4(1)–(3), added par. (15).Enacted provision · exact public law section
(1) in paragraph (13), by striking “or” after the semicolon;Effective date note
Amendment by Pub. L. 111–268 effective 180 days after Oct. 12, 2010, see section 6(a) of Pub. L. 111–268, set out as a note under section 830 of this title.Designer Anabolic Steroid Control Act of 2014
Pub. L. 113–260 § 3(c)(1) · 128 Stat. 2929
Added · 21 U.S.C. § 842(a)(16)
Pub. L. 113–260, § 3(c)(1), added par. (16)
Source evidence
Code amendment note
Subsec. (a)(16). Pub. L. 113–260, § 3(c)(1), added par. (16).Enacted provision · exact public law section
(1) in subsection (a)— (A) in paragraph (14), by striking “or” at the end; (B) in paragraph (15), by striking the period at the end and inserting “; or”; and (C) by inserting, after paragraph (15), the following: “(16) to violate subsection (e) of section 825 of this title.” ; andDesigner Anabolic Steroid Control Act of 2014
Pub. L. 113–260 § 3(c)(2)(A) · 128 Stat. 2929
Inserted · 21 U.S.C. § 842(c)(1)(A)
Pub. L. 113–260, § 3(c)(2)(A), inserted “, (C), or (D)” after “subparagraph (B)”
Source evidence
Code amendment note
Subsec. (c)(1)(A). Pub. L. 113–260, § 3(c)(2)(A), inserted “, (C), or (D)” after “subparagraph (B)”.Enacted provision · exact public law section
(A) by inserting, in subparagraph (A), after “subparagraph (B)” the following: “, (C), or (D)”; andDesigner Anabolic Steroid Control Act of 2014
Pub. L. 113–260 § 3(c)(2)(B) · 128 Stat. 2929
Added · 21 U.S.C. § 842(c)(1)(C); 21 U.S.C. § 842(c)(1)(D)
Pub. L. 113–260, § 3(c)(2)(B), added subpars. (C) and (D)
Source evidence
Code amendment note
Subsec. (c)(1)(C), (D). Pub. L. 113–260, § 3(c)(2)(B), added subpars. (C) and (D).Enacted provision · exact public law section
(B) Definitions. by inserting after subparagraph (B) the following: “(C) In the case of a violation of paragraph (16) of subsection (a) of this section by an importer, exporter, manufacturer, or distributor (other than as provided in subparagraph (D)), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of paragraph (16) of subsection (a). “(D) In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of paragraph (16) of subsection (a) of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term ‘at the retail level’ refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of such paragraph (16) of subsection (a) shall be considered a separate violation.” .Using Data To Prevent Opioid Diversion Act of 2018
Pub. L. 115–271 § 3273(c)(1) · 132 Stat. 3894
Added · 21 U.S.C. § 842(a)(17)
Pub. L. 115–271, § 3273(c)(1), added par. (17)
Source evidence
Code amendment note
Subsec. (a)(17). Pub. L. 115–271, § 3273(c)(1), added par. (17).Enacted provision · exact public law section
(1) in subsection (a)— (A) in paragraph (15), by striking “or” at the end; (B) in paragraph (16), by striking the period at the end and inserting “; or”; and (C) by inserting after paragraph (16) the following: “(17) in the case of a registered manufacturer or distributor of opioids, to fail to review the most recent information, directly related to the customers of the manufacturer or distributor, made available by the Attorney General in accordance with section 307(f).” ; andUsing Data To Prevent Opioid Diversion Act of 2018
Pub. L. 115–271 § 3273(c)(2)(A) · 132 Stat. 3894
Added · 21 U.S.C. § 842(c)(1)(B)
Pub. L. 115–271, § 3273(c)(2)(A), added subpar. (B)
Struck · 21 U.S.C. § 842(c)(1)(B)
Pub. L. 115–271, § 3273(c)(2)(A), struck out former subpar. (B) which read as follows: “In the case of a violation of paragraph (5) or (10) of subsection (a), the civil penalty shall not exceed $10,000.”
Source evidence
Code amendment note
Subsec. (c)(1)(B). Pub. L. 115–271, § 3273(c)(2)(A), added subpar. (B) and struck out former subpar. (B) which read as follows: “In the case of a violation of paragraph (5) or (10) of subsection (a), the civil penalty shall not exceed $10,000.”Enacted provision · exact public law section
(A) in paragraph (1), by striking subparagraph (B) and inserting the following: “(B) (i) Except as provided in clause (ii), in the case of a violation of paragraph (5), (10), or (17) of subsection (a), the civil penalty shall not exceed $10,000. “(ii) In the case of a violation described in clause (i) committed by a registered manufacturer or distributor of opioids and related to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 307(f), the penalty shall not exceed $100,000.” ; andUsing Data To Prevent Opioid Diversion Act of 2018
Pub. L. 115–271 § 3273(c)(2)(B)(i) · 132 Stat. 3894
Inserted · 21 U.S.C. § 842(c)(2)(A)
Pub. L. 115–271, § 3273(c)(2)(B)(i), inserted “or (D)” after “subparagraph (B)”
Source evidence
Code amendment note
Subsec. (c)(2)(A). Pub. L. 115–271, § 3273(c)(2)(B)(i), inserted “or (D)” after “subparagraph (B)”.Enacted provision · exact public law section
(i) in subparagraph (A), by inserting “or (D)” after “subparagraph (B)”; andUsing Data To Prevent Opioid Diversion Act of 2018
Pub. L. 115–271 § 3273(c)(2)(B)(ii) · 132 Stat. 3894
Added · 21 U.S.C. § 842(c)(2)(D)
Pub. L. 115–271, § 3273(c)(2)(B)(ii), added subpar. (D)
Source evidence
Code amendment note
Subsec. (c)(2)(D). Pub. L. 115–271, § 3273(c)(2)(B)(ii), added subpar. (D).Enacted provision · exact public law section
(ii) by adding at the end the following: “(D) In the case of a violation described in subparagraph (A) that was a violation of paragraph (5), (10), or (17) of subsection (a) committed by a registered manufacturer or distributor of opioids that relates to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 307(f), the criminal fine under title 18, United States Code, shall not exceed $500,000.” .
31 of 31 references resolved to an enrolled provision
Editorial Notes
References in Text
Section 825 of this title, referred to in subsec. (a)(16), was so in the original, but probably should have been a reference to section 305 of Pub. L. 91–513, which is classified to section 825 of this title.
Schedules I and II, referred to in subsec. (b), are set out in section 812(c) of this title.
Amendments1978–2018 · 9 rounds
2018
Subsec. (a)(17). Pub. L. 115–271, § 3273(c)(1), added par. (17).
Subsec. (c)(1)(B). Pub. L. 115–271, § 3273(c)(2)(A), added subpar. (B) and struck out former subpar. (B) which read as follows: “In the case of a violation of paragraph (5) or (10) of subsection (a), the civil penalty shall not exceed $10,000.”
Subsec. (c)(2)(A). Pub. L. 115–271, § 3273(c)(2)(B)(i), inserted “or (D)” after “subparagraph (B)”.
Subsec. (c)(2)(D). Pub. L. 115–271, § 3273(c)(2)(B)(ii), added subpar. (D).
2014
Subsec. (a)(16). Pub. L. 113–260, § 3(c)(1), added par. (16).
Subsec. (c)(1)(A). Pub. L. 113–260, § 3(c)(2)(A), inserted “, (C), or (D)” after “subparagraph (B)”.
Subsec. (c)(1)(C), (D). Pub. L. 113–260, § 3(c)(2)(B), added subpars. (C) and (D).
2010
Subsec. (a). Pub. L. 111–268, § 4(4), inserted “For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title.” at end of concluding provisions.
Subsec. (a)(10). Pub. L. 111–268, § 5, inserted “or negligently to fail to self-certify as required under section 830 of this title” before semicolon.
Subsec. (a)(15). Pub. L. 111–268, § 4(1)–(3), added par. (15).
2006
Subsec. (a)(12) to (14). Pub. L. 109–177, § 711(f)(1)(A), added pars. (12) to (14).
Subsec. (b). Pub. L. 109–177, § 714, inserted “, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical,” after “manufacture a controlled substance in schedule I or II” in introductory provisions.
Subsec. (c)(4). Pub. L. 109–177, § 711(f)(2), added par. (4).
2002
Subsec. (c)(2)(A). Pub. L. 107–273, § 4002(d)(2)(B)(i), substituted “under title 18” for “of not more than $25,000”.
Subsec. (c)(2)(B). Pub. L. 107–273, § 4002(d)(2)(B)(ii), substituted “under title 18” for “of $50,000”.
Subsec. (c)(2)(C). Pub. L. 107–273, § 4002(b)(16), realigned margins.
1998
Subsec. (a)(5). Pub. L. 105–277, § 101(b) [title I, § 117(1)], inserted “negligently” before “fail”.
Subsec. (a)(10). Pub. L. 105–277, § 101(b) [title I, § 117(2)], inserted “negligently” before “to fail”.
Subsec. (c)(1). Pub. L. 105–277, § 101(b) [title I, § 117(3)], designated existing provisions as subpar. (A), inserted “subparagraph (B) of this paragraph and” before “paragraph (2)”, and added subpar. (B).
1996
Subsec. (a). Pub. L. 104–237, § 205(a), added par. (11) and closing provisions.
Subsec. (c)(2)(C). Pub. L. 104–237, § 205(b), added subpar. (C).
1988
Subsec. (a)(8). Pub. L. 100–690, § 6056(a), inserted “, or to use to his own advantage or reveal (other than as authorized by section 830 of this title) any information that is confidential under such section” after “protection”.
Subsec. (a)(9). Pub. L. 100–690, § 6056(b), amended par. (9) generally. Prior to amendment, par. (9) read as follows: “to distribute or sell piperidine in violation of regulations established under section 830(a)(2) of this title, respecting presentation of identification.”
Subsec. (a)(10). Pub. L. 100–690, § 6056(d), added par. (10).
Subsec. (c)(2)(C). Pub. L. 100–690, § 6056(c), struck out subpar. (C) which read as follows: “Subparagraphs (A) and (B) shall not apply to a violation of subsection (a)(5) of this section with respect to a refusal or failure to make a report required under section 830(a) of this title (relating to piperidine reporting).”
1978
Subsec. (a)(9). Pub. L. 95–633, § 202(b)(1), added par. (9).
Subsec. (c)(2)(C). Pub. L. 95–633, § 202(b)(2), added subpar. (C).
Statutory Notes and Related Subsidiaries
Effective Date of 2010 Amendment
Amendment by Pub. L. 111–268 effective 180 days after , see section 6(a) of Pub. L. 111–268, set out as a note under section 830 of this title.
Effective Date of 1988 Amendment
Amendment by Pub. L. 100–690 effective 120 days after , see section 6061 of Pub. L. 100–690, set out as a note under section 802 of this title.
Effective Date of 1978 Amendment
Amendment by Pub. L. 95–633 effective , see section 203(a) of Pub. L. 95–633 set out as an Effective Date note under section 830 of this title.
Effective Date
Section effective on first day of seventh calendar month that begins after , see section 704 of Pub. L. 91–513, set out as a note under section 801 of this title.
Repeals
Pub. L. 96–359, § 8(b), , 94 Stat. 1194, repealed section 203(d) of Pub. L. 95–633, which had provided for the repeal of subsecs. (a)(9) and (c)(2)(C) of this section effective .
Credits
1970–2018 · 10 acts
- 1970Pub. L. 91–513, title II, § 402, , 84 Stat. 1262
- 1978Pub. L. 95–633, title II, § 202(b)(1), (2), , 92 Stat. 3776
- 1988Pub. L. 100–690, title VI, § 6056, , 102 Stat. 4318
- 1996Pub. L. 104–237, title II, § 205, , 110 Stat. 3103
- 1998Pub. L. 105–277, div. A, § 101(b) [title I, § 117], , 112 Stat. 2681–50, 2681–68
- 2002Pub. L. 107–273, div. B, title IV, § 4002(b)(16), (d)(2)(B), , 116 Stat. 1808, 1809
- 2006Pub. L. 109–177, title VII, §§ 711(f)(1)(A), (2), 714, , 120 Stat. 262–264
- 2010Pub. L. 111–268, §§ 4, 5, , 124 Stat. 2847, 2848
- 2014Pub. L. 113–260, § 3(c), , 128 Stat. 2931
- 2018Pub. L. 115–271, title III, § 3273(c), , 132 Stat. 3953.
Show as published
(Pub. L. 91–513, title II, § 402, , 84 Stat. 1262; Pub. L. 95–633, title II, § 202(b)(1), (2), , 92 Stat. 3776; Pub. L. 100–690, title VI, § 6056, , 102 Stat. 4318; Pub. L. 104–237, title II, § 205, , 110 Stat. 3103; Pub. L. 105–277, div. A, § 101(b) [title I, § 117], , 112 Stat. 2681–50, 2681–68; Pub. L. 107–273, div. B, title IV, § 4002(b)(16), (d)(2)(B), , 116 Stat. 1808, 1809; Pub. L. 109–177, title VII, §§ 711(f)(1)(A), (2), 714, , 120 Stat. 262–264; Pub. L. 111–268, §§ 4, 5, , 124 Stat. 2847, 2848; Pub. L. 113–260, § 3(c), , 128 Stat. 2931; Pub. L. 115–271, title III, § 3273(c), , 132 Stat. 3953.)